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Background: Malaria and HIV infections are both highly prevalent in sub-Saharan Africa, with HIV-infected patients
being at higher risks of acquiring malaria. The majority of antiretroviral (ART) and anti-malarial drugs are metabolized
by the CYP450 system, creating a chance of drug-drug interaction upon co-administration. Limited data are available
on the effectiveness of the artemether-lumefantrine combination (AL) when co-administered with non-nucleoside
reverse transcriptase inhibitors (NNRTIs). The aim of this study was to compare anti-malarial treatment responses
between HIV-1 infected patients on either nevirapine- or efavirenz-based treatment and those not yet on ART
(control-arm) with uncomplicated falciparum malaria, treated with AL.
Method: This was a prospective, non-randomized, open-label study conducted in Bagamoyo district, with three arms
of HIV-infected adults: efavirenz-based treatment arm (EFV-arm) n = 66, nevirapine-based treatment arm (NVP-arm)
n = 128, and control-arm n = 75, with uncomplicated malaria. All patients were treated with AL and followed up for
28 days. The primary outcome measure was an adequate clinical and parasitological response (ACPR) after treatment
with AL by day 28.
Results: Day 28 ACPR was 97.6%, 82.5% and 94.5% for the NVP-arm, EFV-arm and control-arm, respectively. No early
treatment or late parasitological failure was reported. The cumulative risk of recurrent parasitaemia was >19-fold higher
in the EFV-arm than in the control-arm (Hazard ratio [HR], 19.11 [95% confidence interval {CI}, 10.5–34.5]; P < 0.01). The
cumulative risk of recurrent parasitaemia in the NVP-arm was not significantly higher than in the control-arm ([HR], 2.44
[95% {CI}, 0.79–7.6]; P = 0.53). The median (IQR) day 7 plasma concentrations of lumefantrine for the three arms were:
1,125 ng/m (638.8-1913), 300.4 ng/ml (220.8-343.1) and 970 ng/ml (562.1-1729) for the NVP-arm, the EFV-arm and the
control-arm, respectively (P < 0.001). In all three arms, the reported adverse events were mostly mild.
Conclusion: After 28 days of follow-up, AL was statistically safe and effective in the treatment of uncomplicated malaria
in the NVP-arm. The results of this study also provide an indication of the possible impact of EFV on the performance
of AL and the likelihood of it affecting uncomplicated falciparum malaria treatment outcome.
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Malaria and HIV-1 are the most common infections in
sub-Saharan Africa and to a lesser extent in other develop-
ing countries [1]. It is estimated that about 38 million
Africans are infected with HIV-1 and about 300–500 mil-
lion people suffer from malaria each year [2,3]. World-
wide, the two diseases cause more than four million
deaths per year [1]. HIV infection has been associated
with an increase in malaria parasite density, delayed para-
site clearance, a higher incidence of clinical and severe
malaria, and death [4-12]. Diminished immunity of the
host due to HIV and malaria co-infection may result in
malaria impaired treatment response and an increased risk
of recrudescence and re-infections [6-8,13-20].
The World Health Organization (WHO) recommends
the use of artemisinin-based combination therapy (ACT)
as first-line treatment for uncomplicated falciparum mal-
aria in all malaria-endemic countries [21]. Artemether-
lumefantrine (AL) is one of the most widely used ACT in
malaria-endemic countries for the treatment of uncompli-
cated falciparum malaria, including Tanzania [21]. On the
other hand, triple antiretroviral therapy (ART) is recom-
mended for the management of HIV infection. The com-
plex pharmacology of both ACT and antiretroviral drugs
(ART) creates concerns about the safety and effectiveness
of these agents when used simultaneously [22].
Artemether is metabolized to dihydroartemisinin (DHA)
via cytochrome P450 (CYP) CYP3A4, CYP2B6 and pos-
sibly CYP2A6 [23]. Lumefantrine is metabolized by N-
debutylation, mainly by CYP3A4, to desbutyl-lumefantrine
[23-26]. Nevirapine (NVP) and efavirenz are non-nucleoside
reverse transcriptase inhibitors (NNRTI), and are com-
ponents of most first-line ART regimens in sub-Saharan
Africa. These drugs are metabolized via CYP3A4 and
CYP2B6 and induce their own metabolism via induction
of CYP3A4 and 2B6 [27-30]. The involvement of almost
the same isoenzymes in which some are inhibited and in-
duced while other substances act as substrates or auto-
inducers creates the potential for drug-drug interactions
(DDIs) during co-administration of NNRTI and AL. Un-
favourable DDIs may lead to supra-therapeutic concentra-
tions due to enzyme inhibition resulting in toxicity or,
conversely, sub-therapeutic concentrations resulting in
treatment failure or drug resistance [22]. There may also
be a beneficial interaction leading to positive pharmaco-
logical response in those cases where the parent com-
pound is active and less metabolized.
The treatment guidelines for uncomplicated malaria
set by the National Malaria Control Programmes in sub-
Saharan Africa do not discriminate between the dosing
regimen of AL in non-HIV infected patients and those
undergoing ART.
To date, most of the reported studies describe the ef-
fect of HIV-1 infection on malaria treatment outcome inthe absence of antiretroviral drug treatment [4-7,12-20].
The potential for DDIs between antiretroviral drugs
(ART) and ACT in HIV-1 infected patients without mal-
aria infection has been described in a few studies [31-34].
To date, there is inadequate information on malaria treat-
ment outcome in HIV-1 infected patients on ART. This
study reports the treatment outcomes of uncomplicated
falciparum malaria in HIV-1 infected patients on ART and
those not yet on ART.
Methods
Study site and ethical approval
This study was conducted between May 2010 and
August 2012 at an HIV clinic at Bagamoyo District Hos-
pital. Bagamoyo district is an area of moderate malaria
transmission. In this district, the peak time for mal-
aria transmission peak time is usually around April to
August. The study was approved by the Muhimbili Uni-
versity of Health and Allied Sciences (MUHAS) research
and ethics committee and was conducted according to
Good Clinical Practice. To ensure confidentiality, pa-
tients were identified by special identification numbers.
Study population
This study involved HIV-1 infected adults receiving ART
as 200 mg NVP twice daily or 600 mg EFV at night for
more than two months and those not yet on ART. En-
rolled in the study were 128 patients in the nevirapine-
based treatment arm (NVP-arm), 66 patients in the
efavirenz-based treatment arm (EFV-arm) and 75 pa-
tients not yet on ART (control-arm).
Patients’ eligibility and enrollment
All HIV-1 infected patients presenting at the HIV clinic for
routine medical care, with fever and other symptoms sug-
gestive of uncomplicated falciparum malaria such as chills,
sweats, headaches, muscle aches, nausea, vomiting, diar-
rhoea, body weakness, poor appetite, pallor and enlarged
spleen were screened for eligibility. Patients were only en-
rolled into the study after meeting the inclusion criteria:
Aged ≥ 18 years; reported fever within the last 24 hours
and/or an axillary temperature ≥ 37.5°C and with any of
the above-mentioned symptoms of uncomplicated falcip-
arum malaria; haemoglobin ≥ 7 g/dl and ≥ 35 kg body
weight; microscopically-confirmed Plasmodium falciparum
with no signs of complicated (severe) malaria; no history of
an allergic reaction or serious side effects to AL or treat-
ment with anti-malarial drugs for at least four weeks prior
to enrollment; no evidence of chronic diseases, such as
renal or liver failure; not on anti-tuberculosis drugs for at
least three months prior to enrollment; not pregnant or
a nursing mother; easy accessibility to the health-care facil-
ity (travel time < 2 hours) and willingness to attend for
the stipulated follow-up visits. Before enrollment, written
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tient information was recorded in a case report form
(CRF). The enrolled patients were encouraged to take their
ART and AL as prescribed.
Study design, treatment and procedures
This was a prospective, non-randomized, open-label,
parallel and three-arm study. Patients were followed up
for 28 days. Patients meeting the inclusion criteria were
enrolled and took the full dose (three-day course) of AL
(Coartem® containing 80 mg of artemether and 480 mg
of lumefantrine, Novartis-Basel, Switzerland) at 0, 8, 24,
36, 48 and 60 hrs. The first and fifth doses of AL were
taken by direct observed therapy (DOT) with 250 ml of
milk (3.5% fat). The other four doses were taken at
home. All patients were given verbal instructions on
dosing intervals and on the importance of combining
treatment with fatty meals. Additionally, patients were
supplied with 10 extra 250 ml packets of milk (3.5% fat)
to be taken with the rest of the doses at home. For the
first and fifth doses, which were given by DOT and para-
cetamol was administered to all febrile patients.
Patients involved in this study were counseled to ab-
stain from using alcohol, tea, caffeine and any drugs
which may induce CYP3A4, such as griseofulvin, pred-
nisolone, phenytoin, carbamezapine and phernobarbital.
Non-prescription drugs, herbal medicines, oral contra-
ceptives, grapefruits or grapefruit juice were also prohib-
ited during the study.
At enrollment all patients gave a finger-prick blood sam-
ple for thick smear and for haemoglobin (Hb) estimation.
Blood slides for malaria parasites were all read at Ifakara
Health Institute-Bagamoyo Research and Training Centre
(IHI-BRTC). Venous blood was collected at pre-determined
times for quantification of lumefantrine plasma concentra-
tions. Patients’ baseline CD4+ cell count was obtained from
their records, the timeline being within 3 months prior to
study enrollment.
Laboratory and clinical assessments were conducted
on days 2, 3, 7, 14, 21 and 28 or on any day of recurrent
illness. A reminder was sent to all patients by a study
nurse via telephone about their medication and study
visit schedules. Patients were encouraged to return to
the study site any time they felt ill. Patients who failed to
return on the scheduled day were visited and assessed at
home. If the study nurse failed to locate a patient’s
house, they were classified as lost to follow-up. Any add-
itional medications taken during the study period were
documented in the CRF.
The time to recurrent parasitaemia or the risk of re-
current parasitaemia (RP) was defined as the number of
days between taking the first dose of AL and the day of
microscopically detecting malaria parasites in the thick
blood film. The time at risk ended whenever one of thefollowing conditions occurred: RP, loss to follow-up,
withdrawal, or end of follow-up period [35].
Patients with microscopically-confirmed P. falciparum
during the 28 days of follow-up were treated with either
quinine tablets or injection as described in the malaria
treatment guidelines (2006) of Tanzania [36].
Laboratory procedures
Microscopy
All thick blood smears were stained with 10% Giemsa
stain for 30 minutes. Parasite density was estimated by
counting the number of asexual parasites per 200 (per
1,000 for gametocytes) white blood cells (WBC) on a thick
smear. Parasite density per μl was calculated by assuming
a WBC count of 8,000 per μl [37]. All thick blood smears
were independently read by two experienced microsco-
pists. A smear was declared negative if no asexual para-
sites were seen after examining 200 high-power fields. An
additional reading was performed for discordant results.
Blood sample collection and determination of lumefantrine
concentrations
Blood samples from patients (4 ml) were collected in hep-
arinized vacutainer tubes and centrifuged (×2000 g for
10 min) immediately to obtain plasma. Aliquots of plasma
were transferred into 1 ml cryo-tubes, and stored at −80°C
at the Ifakara Health Institute–BRTC until transfer to
MUHAS for analysis. All patients’ plasma samples were
analyzed at the MUHAS-Sida bio-analytical laboratory in
Dar es Salaam. Lumefantrine concentrations were quanti-
fied using an HPLC method with UV detection as previ-
ously reported [38]. The coefficients of variation (CV%)
during the analysis of lumefantrine were 2.5, 4.2 and 1.8%
at 100, 1000, and 8,000 ng/ml, respectively. The lower
limit of quantification was 50 ng/ml.
Outcome measures
An adequate clinical and parasitological response in pa-
tients at 28 days after anti-malarial treatment was the
primary study objective. The WHO guidelines for as-
sessment and monitoring of anti-malarial drug efficacy
for the treatment of uncomplicated falciparum malaria
were used in the evaluation of the time to RP after
treatment with AL [39]. Accordingly, the classification
of treatment outcome was based on these guidelines.
Adequate clinical and parasitological response (ACPR)
was defined as the absence of parasitaemia by day 28 after
initial treatment irrespective of axillary temperature,
and not meeting any previous criteria for early treat-
ment failure (ETF), late clinical failure (LCF), or late
parasitological failure (LPF). The secondary outcome
was day 7 lumefantrine plasma concentrations and the
safety endpoint, which included clinical and laboratory
adverse events.
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This study was considered to be exploratory. In total,
269 HIV-1 infected adult patients with uncomplicated
falciparum malaria were enrolled with a minimum sam-
ple size of at least 50 patients for each arm [39]. The
data was double-entered into a Microsoft access data-
base, verified and exported to SPSS (version 16.0) soft-
ware. The intention-to-treat approach was used to
analyze the anti-malarial treatment response. The cumu-
lative risk of RP was estimated using the Kaplan-Meier
product limit formula and data were censored. Categor-
ical variables were compared using the chi-square test.
Descriptive statistics were used where appropriate. Con-
tinuous variables were compared using the one-way
ANOVA test. Data is presented as frequencies, medians




A total of 1,528 patients presenting at the HIV clinic with
fever and other symptoms suggestive of malaria infection
were screened. Among the screened patients, 316 (21%)
had positive thick blood smears for malaria parasite. In
total 269 (85%) patients met the inclusion criteria and
were enrolled (Figure 1). In the studied population, 85
(31.6%) patients were males and 184 (68.4%) were females.
Baseline clinical and demographic data showed no signifi-
cant difference between the three arms (Table 1). Among
the enrolled patients, 91% had baseline parasite density
of ≤ 2,000/μl and one patient had ≥260,000/μl. Despite the
high baseline parasitaemia, this patient had no general
danger signs indicating severe disease.
The frequency of fever during the whole period of fol-
low up was higher in the EFV-arm than in the NVP-arm
or the control-arm, but the differences were not statisti-
cally significant (P = 0.82).
In the current study, about 48% of the enrolled pa-
tients had CD4 cell counts of < 350 cells/μl. Patients with
high parasitaemia had low CD4 cell counts and there
was a strong association between CD4 cell counts and
parasitaemia (P < 0.001).
Treatment outcomes
No early treatment failure or late parasitological failure
was observed in the three arms. Overall, after day 28 of
follow-up, 97.6% (95% CI, 92%–99%), 82.5% (95% CI,
70%–90%) and 94.5% (95% CI, 86%–98%) of patients in
the NVP-arm, EFV-arm and control-arm, respectively,
had no recurrent parasitaemia, thus meeting the WHO
criteria for ACPR. The differences in the treatment out-
come in the three arms were highly statistically significant
(P < 0.001) (Table 2). The cumulative risk of recurrent
parasitaemia on day 28 after initiation of treatment in thestudy population as a whole was about 7%. However, the
cumulative risk of recurrent parasitaemia on day 28 after
initiation of treatment was >19-fold higher in the EFV-
arm than in the control-arm (Hazard ratio [HR], 19.11
[95% confidence interval {CI}, 10.5–34.5]; P < 0.01). Con-
versely, the cumulative risk of recurrent parasitaemia in
the NVP-arm was not significantly higher than in the
control-arm (Hazard ratio [HR], 2.44 [95% {CI}, 0.79–7.6];
P = 0.53) (Figure 2). In all three arms, there were no statis-
tically significant differences in the risk of RP between pa-
tients with CD4 counts of > 350 cells/μl compared to
those with CD4 counts of < 350 cells/μl (P = 0.204).
Day 7 lumefantrine plasma concentrations
In total, 251 (93%) patients had lumefantrine plasma con-
centrations measured on day 7 after initiation of treatment.
The median (IQR) day 7 plasma concentrations of lumefan-
trine for the three arms were: 1,125 ng/ml (638.8-1913),
300.4 ng/ml (220.8-343.1) and 970 ng/ml (562.1-1729) for
the NVP and EFV-based treatment arms and for the
control-arm, respectively. The difference in day 7 lumefan-
trine plasma concentrations between the EFV-arm and the
control-arm was statistically significant (P < 0.001), while
there was no statistically significance difference in the
day 7 lumefantrine concentration between the NVP-
arm and the control-arm (P = 0.063). In all three arms,
the median lumefantrine concentration was significantly
lower in patients with RP as compared to those with no RP
(Figures 3). Overall, 4% (3/69) of patients in the control-
arm, 32% (19/60) in the EFV-arm and 3% (4/121) in the
NVP-arm had lumefantrine concentrations of ≤ 280 ng/ml.
Seven out of the eight patients with RP on day 7 had lume-
fantrine concentrations of < 280 ng/ml.
Adverse events
AL was well tolerated in the study population. The most
frequently reported adverse events were mild in severity;
the frequencies of adverse events for the three arms are
indicated in Table 3.
Discussion
In areas of high or moderate malaria transmission, re-
sponse to malaria treatment mainly depends on the host’s
immunity and the amount of drugs available in human
plasma to clear the parasites. Patients with good immunity
have the advantage of getting an adequate malaria cure
with drug(s) as opposed to a subject with poor immunity.
However, in patients with poor immunity, the initial rate
of parasite clearance is determined by the intrinsic activity
of the drug, the susceptibility of infecting parasites and
the drug levels achieved [40]. The pattern of treatment
failure is also determined by the above-mentioned factors.
Possible DDIs between ACT and NNRTIs in HIV-1
patients without malaria have been reported in a few
Figure 1 Study profile.
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effect of NNRTIs on anti-malarial treatment response in
HIV-1 infected adult patients with uncomplicated falcip-
arum malaria in an area of moderate transmission.
In the present study, all patients from the three arms
were treated with artemether-lumefantrine and followed
up for 28 days to determine malaria treatment responseTable 1 Patient baseline characteristics
Parameters Control group
(n = 75)
Sex (female) % 65
Median age in years 38 (19–64)
Temperature mean, SD ± °C 38.1 ± 0.8
Median Weight (IQR) 56 (41–92)
Geometric mean parasite density, parasites/μL, SD ± 1280 (560–4040
Haemoglobin (g/dL) median (IQR) 13.9 (12.2-15.2)
CD4+ count (x106/L) median (IQR) 402 (66–964)(ACPR). Based on WHO recommendations, the cure rates
for P. falciparum malaria for a first-line drug in non-HIV
patients should be at least 90% and preferably >95% [39].
Various studies have shown that the day 28 parasitological
cure rate in non-HIV infected patients with P. falciparum
treated with AL is >95% [41]. Under the WHO guidelines
[39], this study shows an 82.5%, 97.6% and 94.5% ACPRARMS P-value
Patient on NVP Patient on EFV
(n = 128) (n = 66)
79.5 52.3
42 (21–67) 43 (39–66) 0.015
37.8 ± 1.3 38.3 ± 0.9 0.485
55 (41–78) 58 (36–84) 0.953
) 4040 (600–261520) 3440 (480–126960) 0.564
12.1 (11.2-13.5) 12.3 (10.2-13.6) 0.036
354 (19–1781) 298 (9–694) 0.002
Figure 2 Kaplan Meier curve showing cumulative risk of
treatment failure in HIV-1 infected patients treated
with artemether-lumefantrine.
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arm, respectively. Patients in the EFV-arm had a high risk
of recurrent parasitaemia and low day 7 lumefantrine
plasma concentrations compared to the NVP-arm and the
control-arm. Similar results were expected in the NVP-
arm and the EFV-arm; however, a better ACPR was ob-
served in the NVP-arm.
The observed results in the EFV-arm may be due to
possible DDIs between EFV and lumefantrine during the
course of treatment as a result of the induction of com-
mon metabolic enzyme CYP3A4, leading to increased
clearance of lumefantrine and artemether [28-30,42].
Artemether is responsible for parasite biomass reduction
and lumefantrine for cure rate in uncomplicated falcip-
arum malaria [24-26]. Although, NVP and EFV are both
reported to be inducers of CYP3A4 and CYP2B6, the
induction capacity is reported to be disproportionate.
EFV is reported to significantly induce both CYP2B6
and CYP3A4 [29], as opposed to NVP, which strongly
induces CYP2B6 than CYP3A4 [43,44]. The differences
in the induction capacity of CYP3A4 enzyme might ex-
plain the observed differences in the reduction of day 7Table 2 Comparison of treatment outcomes among HIV-1










ETF n, (%) 0 0 0
LTF n, (%) 3 (2.4) 11 (17.5) 4 (5.5)
LPF n, (%) 0 0 0
ACPR n, (%) 122 (97.6) 52 (82.5) 69 (94.5)
RR = 0.4, 95%
C.I = 0.29-0.9, P = 0.53
RR = 3.2, 95% CI,
2.4-7.8, P < 0.001lumefantrine plasma concentrations and, ultimately, the
ACPR between the two arms.
These results are in agreement with findings from pre-
vious studies, which indicated a possible malaria treat-
ment failure in patients treated with AL and EFV [34,45]
and better malaria treatment outcome in patients taking
AL and NVP [33,34].
Lumefantrine absorption varies considerably among
individuals with its bioavailability being improved by
fatty meal intake. As this study was unsupervised, poor
adherence to treatment or inadequate fatty meal intake
might have contributed to the observed sub-optimal day
7 lumefantrine plasma concentrations in the three arms,
thus increasing the risk of recurrent parasitaemia. How-
ever, an AL cure rate of >96% was recently reported irre-
spective of whether it was given under supervision, with
food or unsupervised [46].
Differences in immune status among the studied
population might have also contributed to the observed
differences in the ACPR between the three arms. Pa-
tients in the EFV-arm had lower mean CD4 cell counts
compared with those in the NVP and control-arms, al-
though the differences did not reach statistical signifi-
cance (P = 0.629). This is in line with previous reports
[11,17]. Studies have shown that patients with CD4 cell
counts < 300 cell/μl are at high risk of re-infection rather
than recrudescence when treated with AL [12,14,47-49].
Because, in the present study, parasite genotyping was not
done to distinguish recrudescences from re-infection, the
possibility of recrudescence cannot be excluded, in pa-
tients with day 7 lumefantrine plasma concentrations
below the therapeutic cut-off point [24,25]. Day 7 lume-
fantrine plasma concentration is a surrogate marker for
AUC and lumefantrine AUC correlates well with the treat-
ment response and reflects the degree of exposure of
the parasite to lumefantrine after artemether clearance
[24,25]. Parasites are more likely to survive and multiply
when the drug concentration in a patient’s blood is below
the minimum inhibitory concentration to keep down their
multiplication rate. The surviving parasites will then re-
expand as the drug is eliminated and concentrations fall
further, eventually causing a recrudescence [50]. In the
present study this cut-off point associated well with RP;
seven out of eight patients with recurrent parasitaemia on
day 7 had lumefantrine day 7 plasma concentrations
below this threshold.
Malaria parasite density was slightly higher among pa-
tients in both the NVP-arm and the EFV-arm than in
the control-arm, although this difference was not statis-
tically significant. Lower CD4 cell counts in the EFV and
NVP-arms than in the control-arm might also have con-
tributed to higher parasite density. This finding is in
agreement with other studies, which documented higher
parasite density with decreased immunity among HIV-1
Figure 3 Box plots of day 7 lumefantrine plasma concentrations versus parasite re-appearance in all the three-arms.
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study, patients with recurrent parasitaemia during the
28 days of follow-up had a high baseline parasite count
(BPC). Ezzet et al. reported high risks of recrudescence in
patients with high BPC and low plasma concentration of
lumefantrine [51].
While the results presented and discussed above are of
clinical importance in improving the quality of life for
HIV-1 infected patients on ART with uncomplicated fal-
ciparum malaria and treated with AL, nevertheless, they
are not without limitations. In the present study, the en-
rolled patients were carefully screened for fever history,
the presence or absence of other obvious causes of fever
and the researchers carefully followed up guidelines for




Palpitation (percentage) 23 15 12
Dizziness (percentage) 17 13 11
Severe headache (percentage) 4 3 2this cannot rule out the inclusion of patients with low
asymptomatic P. falciparum parasitaemia, while the pre-
sented fever was caused by opportunistic infections. Re-
ports from other studies have indicated that the febrile
illness that occurs more frequently in HIV/AIDS pa-
tients, especially those with low CD4 cell counts, even in
the presence of malaria infection, may be caused not by
malaria but by other opportunistic infections or may be
due to adverse drug reactions, thus complicating the
diagnosis of malaria [8,52-54]. Thus, the presence of
malaria parasitaemia does not confirm malaria as the
sole source of fever in HIV/AIDS patients [52]. Equally,
in studies conducted in Uganda and Tanzania reported a
rate as low as 4% and 8%, respectively for asymptomatic
P. falciparum parasitaemia among ART-treated patients
and healthy people, respectively [55,56].
Decreasing the risk of false negative malaria, especially
in patients with low malaria parasitaemia, using more
sensitive diagnostic methods such as the malaria rapid
diagnostic test (MRDT) and quantitative real-time poly-
merase chain reaction (PCR), could have complimented
the thick blood smear film method. However, the MRDT
and PCR are not without limitations as it is in the case
of thick blood film. The accuracy of RDT for the
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ported to be equal or superior to routine microscopy
(but inferior to expert microscopy) and do not generate
all information provided by microscopy [57]. The thick
blood film method used in the current study has been
reported to have high specificity and with a sensitivity of
up to 4 to 20 parasites/μL of blood with experienced mi-
croscopist [58,59].
Thick blood films have been reported to give conflict-
ing results in various studies [60-62]. However, such
conflicting results could be minimized by the use of ex-
perienced microscopist and increasing examination
time/number of microscopic fields examined [63]. In
addition, false positive and negative have been reported
with the use of MRDT. False negative malaria have been
reported in patients with low parasitaemia (<200 para-
site/ul), very high parasitaemia (prozone effect), in case
of histidine rich protein 2 of P. falciparum deficiency
(Pfhrp2 gene deletions) and due to cross-reactions be-
tween Plasmodium species. The sensitivity of MRDT has
been reported to be reduced to < 75% with < 1000 para-
sites/μl [57,64,65]. False positive malaria has been re-
ported in patients with other infections, with auto-
antibodies (rheumatoid factor), presence of gametocytes
and due to persistence of PfHRP2 in the blood stream for
a period of up to one month following successful malaria
parasite clearance by anti-malarial treatment or self-
cleared infection [57,62,64,66]. The PCR has been re-
ported to overestimate malaria [67]. This study involved
highly experienced microscopists therefore, the use of
thick blood film as solely diagnostic tool might have not
adversely affected malaria results. WHO and other guide-
lines recommend the use of experienced microscopists
and light microscope as primary method of malaria diag-
nosis in endemic areas [36,61,64,68].
In the present study, malaria parasites were not geno-
typed to differentiate recrudescence from re-infection
[39]; in areas of high or moderate malaria transmission,
RP are probably due to new infectious bites [35]. Thus,
the ACPR (AL effectiveness) reported here might have
increased in the three arms studied if these results had
been corrected by PCR for re-infection.
In conclusion, the findings of this study suggest that
AL is safe and effective in the treatment of uncompli-
cated falciparum malaria in patients receiving NVP-
based ART compared to those receiving EFV-based
ART. The results of this study also provide an indication
of the possible impact of EFV on the performance of AL
and the likelihood of it affecting malaria treatment out-
come. Surveillance on the effectiveness and efficacy of
AL in HIV infected patients, particularly those on EFV-
based ART, should be performed in order to elucidate
the role of the latter in the treatment outcome of un-
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